- Home
- NYXH vs UPB Comparison
NYXH vs UPB Comparison
Compare NYXH & UPB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NYXH
- UPB
- Stock Information
- Founded
- NYXH 2009
- UPB 2021
- Country
- NYXH Belgium
- UPB United States
- Employees
- NYXH N/A
- UPB N/A
- Industry
- NYXH Medical/Dental Instruments
- UPB
- Sector
- NYXH Health Care
- UPB
- Exchange
- NYXH Nasdaq
- UPB NYSE
- Market Cap
- NYXH 394.1M
- UPB 457.2M
- IPO Year
- NYXH 2021
- UPB 2024
- Fundamental
- Price
- NYXH $10.35
- UPB $7.98
- Analyst Decision
- NYXH Strong Buy
- UPB Strong Buy
- Analyst Count
- NYXH 5
- UPB 4
- Target Price
- NYXH $17.00
- UPB $56.50
- AVG Volume (30 Days)
- NYXH 30.4K
- UPB 239.8K
- Earning Date
- NYXH 03-13-2025
- UPB 03-04-2025
- Dividend Yield
- NYXH N/A
- UPB N/A
- EPS Growth
- NYXH N/A
- UPB N/A
- EPS
- NYXH N/A
- UPB N/A
- Revenue
- NYXH $5,668,079.00
- UPB $2,207,000.00
- Revenue This Year
- NYXH $22.93
- UPB N/A
- Revenue Next Year
- NYXH $411.04
- UPB N/A
- P/E Ratio
- NYXH N/A
- UPB N/A
- Revenue Growth
- NYXH 32.65
- UPB 82.10
- 52 Week Low
- NYXH $6.76
- UPB $6.65
- 52 Week High
- NYXH $20.00
- UPB $29.46
- Technical
- Relative Strength Index (RSI)
- NYXH 51.74
- UPB N/A
- Support Level
- NYXH $10.47
- UPB N/A
- Resistance Level
- NYXH $10.92
- UPB N/A
- Average True Range (ATR)
- NYXH 0.41
- UPB 0.00
- MACD
- NYXH -0.11
- UPB 0.00
- Stochastic Oscillator
- NYXH 4.61
- UPB 0.00
About NYXH Nyxoah SA
Nyxoah SA is a health-technology company focused on the development and commercialization of solutions and services to treat sleep disordered breathing conditions. Nyxoah's solution platform is based on the Genio system, a CE-Mark validated, user-centered, bilateral neurostimulation therapy to treat moderate to severe Obstructive Sleep Apnea (OSA), the common sleep disordered breathing condition that is associated with increased mortality risk and comorbidities including cardiovascular diseases, depression and stroke.
About UPB UPSTREAM BIO INC
Upstream Bio Inc is a clinical-stage biotechnology company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders. It is developing verekitug, the known antagonist currently in clinical development that targets the receptor for Thymic Stromal Lymphopoietin (TSLP), a cytokine which is a clinically validated driver of inflammatory response positioned upstream of multiple signaling cascades that affect a variety of immune mediated diseases.